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Abstract : Background : Although platinum-combination chemotherapy is widely used to treat advanced non-
small cell lung cancer (NSCLC), not all elderly patients benefit from this regimen. In this retrospective study, 
we aimed to evaluate whether the Glasgow Prognostic Score (GPS), an indicator of systemic inflammation and 
malnutrition, could predict the tolerability and efficacy of platinum-combination chemotherapy among elderly 
patients with NSCLC. Methods : The eligibility criteria included patients aged ≥ 70 years with NSCLC treated 
with first-line platinum-combination chemotherapy at Shimane University Hospital between January 2015 and 
December 2018. Results : Thirty-two patients with NSCLC (median age, 74 years) were included. The GPS scores 
were 0–1 for 19 patients and 2 for 13 patients. Four chemotherapy cycles were completed by 57.9% and 30.8% 
of patients in the GPS 0–1 and GPS 2 groups, respectively. The GPS 0–1 group experienced better outcomes 
than the GPS 2 group (response rate : 26% vs. 15%, P = 0.67 ; median progression-free survival : 4.1 vs. 2.1 months, 
P = 0.0026 ; median overall survival : 22.8 vs. 9.6 months, P = 0.0092). Conclusions : Platinum-combination chemo-
therapy demonstrated promising efficacy among elderly NSCLC patients with a GPS 0–1. Therefore, GPS may 
be crucial in determining whether treatments recommended for younger patients are suitable for older patients 
with NSCLC. J. Med. Invest. 68 : 260-264, August, 2021
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INTRODUCTION
 
Platinum-combination chemotherapy is a widely used 
standard treatment for advanced non-small cell lung cancer 
(NSCLC) (1). The recent development of reduced toxicity in plat-
inum-combinations has broadened its scope by including elderly 
patients (2-5). However, elderly patients experience age-related 
changes along with the development of comorbidities, implying 
that not all elderly patients benefit from platinum-combination 
chemotherapy. For example, although a subset analysis of the 
CA031 study data demonstrated that carboplatin plus nanopar-
ticle albumin-bound paclitaxel is safe and effective among elderly 
patients, a phase II study to assess the efficacy and safety of the 
treatment regimen was interrupted because of treatment-relat-
ed mortality and serious adverse events among elderly patients 
with NSCLC (4, 6). 
The Glasgow Prognostic Score (GPS) is an indicator of sys-
temic inflammation and malnutrition (7, 8). Fujio et al. retrospec-
tively demonstrated that among patients with advanced NSCLC 
and an Eastern Cooperative Oncology Group performance status 
(PS) of 2, a high GPS was associated with poorer outcomes than 
a low GPS (9). Thus, the GPS may be useful for identifying 
elderly patients with NSCLC who are likely to benefit from 
platinum-combination chemotherapy. The present study aimed 
to evaluate whether the GPS could predict the tolerability and 
efficacy of platinum-combination chemotherapy in elderly pa-
tients with NSCLC. 
PATIENTS AND METHODS
Patients
We retrospectively reviewed elderly patients with NSCLC 
who received platinum-combination chemotherapy as first-line 
treatment at the Shimane University Hospital between January 
2015 and December 2018. The study’s retrospective protocol 
was approved by our Institutional Review Board (approval 
number : 4654, approval date : June 4, 2020), which also waived 
the requirement for informed consent. Based on several previous 
studies, “elderly” patients were defined as being aged ≥ 70 years 
(2, 4, 6). Patients were excluded from this study if they had 
epidermal growth factor receptor gene mutations or anaplastic 
lymphoma kinase fusion genes. 
Assessments
Blood tests were conducted for all patients to determine their 
pretreatment serum concentrations of serum albumin (Alb) and 
C-reactive protein (CRP). Those findings were used to determine 
the GPS scores (7, 8) : a GPS of 0 was defined as patients with 
CRP concentration of < 1.0 mg / dL and Alb concentration of ≥ 3.5 
mg / dL ; a GPS of 1 was defined as patients with CRP concentra-
tion of ≥ 1.0 mg / dL or Alb concentration of < 3.5 mg / dL ; and a 
GPS of 2 as patients with CRP concentration of ≥ 1.0 mg / dL and 
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Alb concentration of < 3.5 mg / dL. In a retrospective study for ad-
vanced patients with NSCLC with a PS of 2, Fujio et al. compared 
the outcomes to a GPS 0–1 group or a GPS 2 group (9). Similarly, 
in our study, the patients were assigned to a GPS 0–1 group 
or a GPS 2 group for the analyses to compare the tolerability 
and efficacy of platinum-combination chemotherapy. Treatment 
responses were retrospectively assessed using version 1.1 of the 
Response Evaluation Criteria in Solid Tumors. Adverse events 
were evaluated using version 5.0 of the Common Terminology 
Criteria for Adverse Events.
Statistical methods 
Progression-free survival (PFS) and overall survival (OS) 
outcomes were evaluated using the Kaplan-Meier method and 
log-rank test. All other analyses were performed using Fisher’s 
exact test. Differences were considered statistically significant 
at P-values of < 0.05. The analyses were performed using JMP 
software (version 10.0 ; SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
The study included 32 patients (29 men and 3 women) with 
a median age of 74 years, and their characteristics are listed in 
Table 1. The GPS 0–1 group included 19 patients (GPS 0 included 
14 patients and GPS 1 included 5 patients), and the GPS 2 group 
included 13 patients. The GPS 0–1 group included 6 patients 
with a PS of 0, 11 with a PS of 1, and 2 with a PS of 2. All 13 
patients in the GPS 2 group had a PS of 1. Chronic obstructive 
pulmonary disease, diabetes mellitus, and heart disease were 
common comorbidities. Most patients received carboplatin as the 
platinum agent. Although there were no significant differences 
in the baseline characteristics of the two groups, the GPS 0–1 
group had higher proportions of female patients, presence of 
other cancers, and interstitial lung disease.
Treatment parameters
The treatment parameters are shown in Table 2. The median 
number of chemotherapy cycles was 4 cycles (range : 1–11 cycles) 
in the GPS 0–1 group and 2 (range : 1–4 cycles) in the GPS 2 
group. Four chemotherapy cycles were completed by 57.9% of 
patients in the GPS 0–1 group and 30.8% in the GPS 2 group. 
The main cause of treatment discontinuation was disease pro-
gression, which was relatively common in the GPS 2 group (7 
patients, 53.4%). 
Efficacy
Table 3 shows the tumor responses. The overall response rates 
(ORRs) were 26.3% in the GPS 0–1 group and 15.4% in the GPS 
2 group ; however, the difference was not significant (P = 0.67). 
The disease control rates were 68.4% in the GPS 0–1 group 
and 23.1% in the GPS 2 group, and most patients in the GPS 2 
group developed progressive disease (10 patients, 76.9%). The 
survival curves are shown in Figures 1 and 2. Patients in the 
GPS 0–1 group had significantly longer median values for PFS 
(4.1 months [95% confidence interval : 2.2-7.4 months] vs. 2.1 
months [95% confidence interval : 0.8-2.7 months], P = 0.0026) 
and OS (22.8 months [95% confidence interval : 8.2-NA months] 
vs. 9.6 months [95% confidence interval : 2.6-14.8 months], 
P = 0.0092). In a subgroup analysis including patients aged ≥75 
years (n = 15), the median PFS in the GPS 0–1 group and the 






Age, years Median (range) 74 (70–84) 74 (70–82)
Sex, n (%) Female 3 (15.8%) 0 (0%)
Histology, n (%) Non-SCC 11 (57.9%) 6 (46.2%)
SCC 8 (42.1%) 7 (53.8%)
Stage, n (%) III 4 (21.0%) 2 (15.4%)
IV 15 (78.9%) 11 (84.6%)
PS, n (%) 0 6 (31.6%) 0 (0%)
1 11 (57.9%) 13 (100%)
2 2 (10.5%) 0 (0%)
Comorbidities, n (%) COPD 8 (42.1%) 5 (38.5%)
DM 6 (31.6%) 6 (46.2%)
Heart disease 6 (31.6%) 4 (30.8%)
Other cancer 7 (36.8%) 1 (7.7%)
ILD 6 (31.6%) 1 (7.7%)
Cerebrovascular disease 4 (21.0%) 2 (15.4%)
Hepatic disease 3 (15.8%) 2 (15.4%)
Platinum agent, n (%) CBDCA 16 (84.2%) 12 (92.3%)
CDDP 3 (15.8%) 1 (7.7%)
Additional drugs, n (%) PEM 5 (26.3%) 5 (38.5%)
Nab-PTX 3 (15.8%) 4 (30.8%)
TS-1 4 (21.0%) 3 (23.1%)
PEM + Bev 4 (21.0%) 0 (0%)
PTX 2 (10.5%) 0 (0%)
GEM 1 (5.3%) 1 (7.7%)
GPS, Glasgow Prognostic Score ; SCC, squamous cell carcinoma ; PS, 
performance status ; COPD, chronic obstructive pulmonary dis-
ease ; DM, diabetes mellitus ; ILD, interstitial lung disease ; CBDCA, 
carboplatin ; CDDP, cisplatin ; PEM, pemetrexed ; nab-PTX, nanoparti-
cle albumin-bound paclitaxel ; TS-1, tegafur / gimeracil / oteracil ; BEV, 
bevacizumab ; PTX, paclitaxel ; GEM, gemcitabine.
Table 2.　Treatment parameters
GPS 0–1 (n = 19) GPS 2 (n = 13)
Median chemotherapy cycles (range) 4 (1–11) 2 (1–4)
Patients who completed 4 cycles, n (%) 11 (57.9%) 4 (30.8%)
Causes of discontinuation
Disease progression, n (%) 4 (21.0%) 7 (53.4%)
Toxicity, n (%) 2 (10.5%) 2 (15.4%)
PS worsening, n (%) 2 (10.5%) 0 (0%)
GPS, Glasgow Prognostic Score ; PS, performance status.
Table 3.　Tumor responses
GPS 0–1 (n = 19) GPS 2 (n = 13) P
CR, n (%) 0 (0%) 0 (0%)
PR, n (%) 5 (26.3%) 2 (15.4%)
SD, n (%) 8 (42.1%) 1 (7.7%)
PD, n (%) 6 (31.6%) 10 (76.9%)
ORR 26.3% 15.4% 0.67
DCR 68.4% 23.1% 0.29
CR, complete response ; PR, partial response ; SD, stable dis-
ease ; PD, progressive disease ; ORR, overall response rate ; DCR, 
disease control rate.
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the median OS in the GPS 0–1 group and the GPS 2 group was 
32.5 and 9.8 months (p = 0.11), respectively.
Additional chemotherapy regimens were administered to 14 
patients (73.7%) in the GPS 0–1 group and 8 (61.5%) in the GPS 
2 group. Immune checkpoint inhibitors (ICIs) were administered 
to 9 patients (47.4%) (programmed death-ligand 1 tumor propor-
tion score was 0% in 3 patients, 1-49% in 2 patients, ≥50% in 1 
patient, and unknown in 3 patients) in the GPS 0–1 group and 6 
patients (46.2%) (programmed death-ligand 1 tumor proportion 
score was 0% in 2 patients, 1-49% in 2 patients, and unknown 
in 2 patients) in the GPS 2 group. In the GPS 0–1 group, ORR 
of ICIs was 22% and 3 patients experienced PFS for more than 
1 year by ICIs. In the GPS 2 group, ORR of ICIs was 0% and 1 
patient experienced PFS for more than 1 year by ICIs.
 
Toxicity
The most common adverse events are shown in Table 4. No 
significant inter-group differences were observed for all grades 
of adverse events. However, both groups had relatively high 
rates of hematological adverse events, except febrile neutropenia, 
with incidences of 15–40% for grade 3–4 hematological adverse 
events. One patient in the GPS 0–1 group experienced febrile 
neutropenia. Although anorexia, constipation, and fatigue were 
common events, few cases involved grade 3 events. No grade 4 
non-hematological adverse events were observed in either of the 
two groups. However, 1 treatment-related death caused by grade 
5 acute kidney injury occurred in the GPS 2 group.
 
DISCUSSION
This retrospective study evaluated whether the GPS could 
efficiently predict the tolerability and efficacy of platinum-com-
bination chemotherapy among elderly Japanese patients with 
NSCLC. The results revealed that the GPS 0–1 group had an 
ORR of 26.3%, a median PFS of 4.1 months, and a median OS of 
22.8 months. These results were comparable to the reported effi-
cacy of platinum-combination chemotherapy among all patients 
with NSCLC, including young patients (3, 10-12). The present 
study revealed that the GPS 2 group had a higher disease pro-
gression rate and shorter PFS and OS intervals than the GPS 
0–1 group. Similarly, in a subgroup analysis of patients aged ≥75 
years, the median PFS and OS of the GPS 0–1 group tended to 
be longer than those of the GPS 2 group (3.2 vs 2.1 months and 
32.5 vs 9.8 months, respectively). There were no significant dif-
ferences observed with regard to adverse events between the two 
groups, and only a few patients experienced febrile neutropenia 
or grade 3 non-hematological adverse events. Moreover, in the 
GPS 2 group, the main cause of treatment discontinuation was 
disease progression, as opposed to toxicity. Thus, platinum-com-
bination chemotherapy might be less effective, but not intolera-
ble, for elderly patients with NSCLC and a GPS of 2.
Although in our study, all patients in the GPS 2 group pos-
sessed a good PS (PS = 1), they experienced poor response to 
treatment and had a poor prognosis. Therefore, for elderly pa-
tients, assessment using the PS alone may be insufficient, and 
the GPS could be a valuable marker for predicting the tolerabil-
ity, efficacy, and prognosis after various treatments for NSCLC 
(7, 8, 13-16). Furthermore, Fujio et al. reported that among 
patients with advanced NSCLC and a PS of 2, a GPS of 2 was 
associated with poorer outcomes than a GPS of 0–1 (9). Based 
on the results of our study and that conducted by Fujio et al., it 
appears that patients with NSCLC with a GPS of 0–1 might 
benefit from standard treatment that is recommended for young-
er patients or patients with a good PS, even if the patient is in a 
high-risk group (older aged or poorer PS). Thus, the GPS might 
be a helpful tool to guide treatment selection for NSCLC among 
patients with higher risk factors. Additionally, the combination 
of platinum-based chemotherapy and ICIs has recently become 
Figure 1.　Kaplan-Meier curves for progression-free survival (PFS) 
according to the Glasgow prognostic score (GPS).
Figure 2.　Kaplan-Meier curves for overall survival (OS) according 
to the Glasgow prognostic score (GPS).
Table 4.　Toxicities










Anemia 19 (100%) 3 (15.8%) 13 (100%) 5 (38.5%)
Thrombocytopenia 12 (63.2%) 4 (21.0%) 10 (76.9%) 3 (23.1%)
Neutropenia 12 (63.2%) 6 (31.6%) 9 (69.2%) 2 (15.4%)










Anorexia 14 (73.7%) 0 (0%) 8 (61.5%) 1 (7.7%)
Constipation 12 (63.2%) 0 (0%) 9 (69.2%) 0 (0%)
Fatigue 11 (57.9%) 0 (0%) 10 (76.9%) 0 (0%)
Nausea 6 (31.6%) 0 (0%) 4 (30.8%) 1 (7.7%)
AST 5 (26.3%) 0 (0%) 5 (38.5%) 0 (0%)
ALT 4 (21.0%) 0 (0%) 3 (23.1%) 0 (0%)
Creatinine 2 (10.5%) 0 (0%) 3 (23.1%) 1 (7.7%)
Rash 2 (10.5%) 0 (0%) 2 (15.4%) 1 (7.7%)
GPS, Glasgow prognostic score ; AST, aspartate transaminase ; ALT, 
alanine transaminase.
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standard therapy for advanced NSCLC (17-19). Therefore, we 
further intend to verify whether the GPS can predict the toler-
ability and efficacy of platinum-based chemotherapy plus ICIs 
among elderly patients with NSCLC.
The present study has several limitations. First, the retrospec-
tive design and small sample size are potential sources of bias. 
Second, the patients were treated using various chemotherapy 
regimens, and the small sample size precluded treatment-spe-
cific sub-analyses. Third, CRP and Alb concentrations are non-
specific markers, and comorbidities can also influence the GPS. 
Therefore, the GPS may not always accurately reflect the condi-
tion of elderly patients with NSCLC. Fourth, additional therapy 
with ICIs might affect the result for OS. The efficacy of ICIs was 
better in the GPS 0–1 group than in the GPS 2 group.
In conclusion, platinum-combination chemotherapy provided 
promising efficacy for elderly patients with NSCLC and a GPS of 
0–1. Thus, elderly patients with NSCLC and a GPS of 0–1 may 
benefit from standard treatment regimens that are generally 
recommended for younger patients.
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